false
0001725430
0001725430
2024-02-29
2024-02-29
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported): February 29, 2024
INTELLIGENT
BIO SOLUTIONS INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-39825 |
|
82-1512711 |
(State
of Incorporation) |
|
(Commission
File Number) |
|
(IRS
employer identification no.) |
142
West, 57th Street, 11th
Floor
New
York, NY 10019
(Address
of principal executive offices, including zip code)
Registrant’s
telephone number, including area code: (646) 828-8258
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, $0.01 par value |
|
INBS |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
1.01 Entry into a Material Definitive Agreement.
On
February 29, 2024, Intelligent Bio Solutions Inc. (the “Company”) entered into a Consulting Agreement (the “C2C Agreement”)
with C2C Advisors Inc. (“C2C”) pursuant to which C2C will provide certain advisory and investor relations services to the
Company. As consideration for such services, the Company agreed pay a fee consisting of: (a) a cash fee of $25,000 per month and (b)
a single grant of 37,500 restricted shares of common stock (the “C2C Grant Shares”). The C2C Agreement has an initial term
of 6 months.
The
foregoing description of the C2C Agreement does not purport to be complete and is qualified in its entirety by reference to the C2C Agreement,
which is attached hereto as Exhibit 10.1 and incorporated by reference herein.
Item
3.02 Unregistered Sales of Equity Securities.
On
February 29, 2024, the Company entered into an Investor Relations and Corporate Development Advisory Agreement (the “ClearThink
Agreement”) with ClearThink Capital LLC (“ClearThink”) pursuant to which ClearThink will provide certain advisory and
investor relations services to the Company. As consideration for such services, the Company agreed pay a fee consisting of: (a) an initial
grant of 5,260 restricted shares of common stock (the “Initial Grant”) and (b) a monthly fee consisting of (i) a cash fee
of a $5,000 per month, and (ii) a grant of restricted common stock with a value of $4,000 per month ($12,000 per three-month period (a
“Quarter”)), with the number of shares of common stock in each such Quarterly issuance (each a “Quarterly Grant”)
calculated on the first business day of each Quarter based on the closing price of the Company’s common stock on the last trading
day of the immediately preceding Quarter. The ClearThink Agreement remains in effect until terminated by either party after three months
from the effective date. The shares issued and issuable in the Initial Grant and the Quarterly Grants have and will be, as applicable,
issued pursuant to an exemption from registration available pursuant to Section 4(a)(2) of the Securities Act of 1933 as amended (the
“Securities Act”).
The
description of the C2C Agreement set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item
3.02. The C2C Grant Shares will be issued pursuant to an exemption from registration available pursuant to Section 4(a)(2) of the Securities
Act.
Item
9.01 Financial Statements and Exhibits.
* |
Certain
information in this document has been excluded pursuant to Regulation S-K, Item 601(a)(5) and Item 601(a)(6). Intelligent Bio
Solutions Inc. hereby agrees to furnish a supplemental copy of any omitted exhibits, schedules or other similar attachments to the
U.S. Securities and Exchange Commission upon request. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date:
March 1, 2024 |
|
|
|
INTELLIGENT
BIO SOLUTIONS INC. |
|
|
|
|
By:
|
/s/
Spiro Sakiris |
|
Name:
|
Spiro
Sakiris |
|
Title: |
Chief
Financial Officer |
Exhibit
10.1
CONSULTING
AGREEMENT
This
Consulting Agreement (“Agreement”) is dated February 29th 2024, (the “Start Date”) BY AND BETWEEN
Intelligent
Bio Solutions Inc. (“Company”, “IBS”)
142
West 57th Street
11th
Floor
New
York, NY 10019
(646)828-8258
AND
C2C
Advisors Inc
(“Consultant”,”C2C”)
Dror
Tepper (the “Representatives”)
dror@ajocapital.com
IN
CONSIDERATION of the mutual covenants and promises contained in this Agreement, the receipt, and sufficiency of which are acknowledged,
and intended to be legally bound, the parties hereby agree as follows:
1.
Consultant Duties. The Consultant and its Representatives shall provide to the Client certain services described in the attached
Exhibit A (the “Services”). In the performance of these duties, the Consultant shall provide the Client with the benefits
of its best judgment and efforts. It is understood and acknowledged by the Parties that the value of the Consultant’s advice is
not measurable in any quantitative manner. Upon the terms and subject to the conditions set forth in this Agreement, the Company hereby
engages the Consultant as an independent contractor to have its Representative consult with and provide advice to, the Company’s
management in respect of matters involving and relating to marketing and such other matters as the Company may reasonably request from
time to time, as more fully set forth on Exhibit A.. The Consultant, in the capacity as an independent contractor under this Agreement,
shall not have any right, power, or authority to bind or commit the Company or any of the Company’s subsidiaries to any act, service,
or other contractual commitment, and the Consultant shall not represent to any other person or entity that Consultant has any such right,
power or authority. In addition, the Consultant shall not have any right, power, or authority to amend or terminate any relationship
between the Company or any of the Company’s subsidiaries and any other person or entity other than those relationships between
the Company and Consultant. The Company retains the right to engage the services of other persons and entities to perform services for
the Company, whether similar or dissimilar to the Services to be provided by the Consultant to the Company. The Consultant retains the
right to perform services for other persons or entities, whether similar or dissimilar to the Services to be provided by the Consultant
to the Company, provided that such services shall not be provided to a competitor of the Company. This Agreement shall be non-exclusive
to both the Company and the Consultant.
2.
Term. The “Term” of this Agreement shall start on the Start Date and continue for six (6) months thereafter, as may
be extended in writing by the parties unless earlier terminated in accordance with this Agreement. Either party may terminate this Agreement
at any time and for any reason, without cause, upon forty-five (45) days prior written notice.
3.
Compensation.
3.1 | The
Company shall pay the Consultant a consulting fee (the “Fee”) consisting
of (a) a monthly cash fee of $25,000 and (b) a single one-time grant of 37,500 restricted
shares of common stock of the Company (the “Shares”)for a campaign duration of
six months. The client acknowledges that all such monies and Shares are deemed fully earned
upon the execution of this Agreement. |
Initiation
of payment is triggered upon signing.
| ● | An
upfront payment covering two months is required to reserve media assets. |
| ● | The
invoicing cycle is established at 60-day intervals paid on the 1st of the month. |
| ● | Shares
issuance within five (5)business days of the hereof date. |
Share
Issuance Information: C2C Capital, Inc.
EIN#:
[***]
3.2 | The
Shares will be restricted stock and contain an appropriate restrictive legend referring to
the restrictions on transfer under the Securities Act of 1933, as amended (the “Act”) |
4.
Consultant Representations. Consultant hereby represents and warrants to the Company as follows:
| a) | The
Shares are being acquired by the Consultant for its account, for investment purposes only
and not with a view to the sale or distribution of all or any part of the Shares, nor with
any present intention to sell or to in any way distribute the Shares. |
| b) | The
Consultant has sufficient knowledge and experience in financial matters so as to be capable
of evaluating the merits and risks of acquiring the Shares. |
| c) | The
Consultant has reviewed copies of such documents and other information as the Consultant
has deemed necessary in order to make an informed investment decision with respect to its
acquisition of the Shares. |
| d) | The
Consultant (a) has had both the opportunity to ask questions and receive answers from the
officers and directors of the Company and all persons acting on its behalf concerning the
Shares and the business of the Company, and (b) is familiar with the business, management,
financial condition and affairs of the Company. |
| e) | The
Consultant understands that the Shares may not be sold, transferred or otherwise disposed
of without registration under the Act or the availability of an exemption therefrom, and
that in the absence of an effective registration statement covering the Shares or an available
exemption from registration under the Act, the Shares must be held indefinitely. Further,
the Consultant understands and has the financial capability of assuming the economic risk
of an investment in the Shares for an indefinite period of time. |
| f) | The
Consultant has been advised by the Company that the Consultant will not be able to dispose
of the Shares, or any interest therein, without first complying with the relevant provisions
of the Act and any applicable state securities laws. |
| g) | The
Consultant understands the provisions of Rule 144 promulgated under the Act, permitting the
routine sales of the securities of certain issuers subject to the terms and conditions thereof. |
| h) | The
Consultant acknowledges that the Company is under no obligation to register the Shares or
to furnish any information or take any other action to assist the undersigned in complying
with the terms and conditions of any exemption which might be available under the Act or
any state securities laws with respect to sales of the Shares in the future. |
| i) | The
Consultant is an “Accredited Investor” as defined in Rule 501 of Regulation D
of the Act. |
5.
Severability. Each provision contained in this Agreement shall be treated as a separate and independent clause, and the unenforceability
of any one clause shall in no way impair the enforceability of any of the other clauses in this Agreement.
6.
Independent Contractor; No Obligation to Hire. The Consultant’s relationship to the Company under this Agreement is solely
that of an independent contractor. The Consultant shall not be considered an employee or agent of the Company under this Agreement or
otherwise. The Consultant acknowledges that, as an independent contractor, the Company will not provide the Consultant with any benefits
that the Company or any of its subsidiaries provides to their respective employees including, without limitation, health insurance, other
health care benefits, sick leave, vacation, or holiday leave. Without limiting the generality of the foregoing, the Consultant shall
be solely responsible for the timely payment of his self-employment and income taxes. The Company shall not have any obligation to deduct
or withhold any tax or employee benefit payments from any amount payable to the Consultant under this Agreement. Nothing contained in
this Agreement or otherwise shall require the Company at any time to make an offer of employment to the Consultant, to hire the Consultant
as an employee, or to retain the services of the Consultant in any other capacity.
7.
Waiver. The waiver of the breach of any term or provision of this Agreement shall not operate as or be construed to be a waiver
of any other or subsequent breach of this Agreement.
8.
Governing Law. This Agreement and all acts and transactions pursuant hereto and the rights and obligations of the parties hereto
shall be governed, construed and interpreted in accordance with the laws of the State of New York, without giving effect to principles
of conflicts of law.
9.
Counterparts. This Agreement may be executed in two counterparts (including by facsimile or other electronic transmissions), each
of which shall be deemed an original but all of which together shall constitute one and the same instrument.
10.
Successors and Assigns. All covenants, promises, and agreements by or on behalf of the parties contained in this Agreement shall
insure to the benefit of, and be binding upon, the successors and permitted assigns of the parties to this Agreement. This Agreement
and any and all of the rights and obligations of the parties may not be assigned without the prior written approval of both parties.
11.
Entire Agreement. This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof
and all promises, representations, understandings, warranties, and agreements with reference to the subject matter of this Agreement
and inducements to the making of this Agreement relied upon by any party to this Agreement have been expressed in this Agreement.
This
Agreement supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto and AJO Capital INC
with respect to the subject matter hereof. This Agreement may not be changed or modified, except by an agreement in writing signed by
both of the parties to this Agreement.
12.
Restrictive Covenants and Need for Protection. Consultant acknowledges that, because of its position with the Company, Consultant
has or will develop knowledge of the affairs of the Company and its subsidiaries and their relationships with dealers, distributors,
and customers such that Consultant could do serious damage to the financial welfare of the Company and/or its subsidiaries should Consultant
compete or assist others in competing with the business of the Company and/or its subsidiaries. Consequently, and in consideration of
the benefits Consultant is to receive under this agreement, and for other good and valuable consideration, the receipt of which Consultant
hereby acknowledges, the Consultant agrees as follows:
12.1
Confidential Information.
12.1.1
“Confidential Information” means all information and know-how, regardless of whether in writing, relating to the business,
technical, financial, or other affairs of the Company or its representatives, customers, potential customers, suppliers or potential
suppliers that the Company delivers or otherwise makes available to the Consultant or that has or may come into the possession of the
Consultant, including, without limitation, any invention, method, technique, project, development, plan, vendor information, customer
information, equipment, trade secret, process, research, reports, financial data, technical data, computer program, software, software
code, software documentation, hardware design, technology, marketing or business plan, forecast, financial statement, budget, price,
cost or personnel data.
12.1.2
Obligations. The Consultant shall keep confidential the Confidential Information and (1) shall use at least the same degree of
care in safeguarding the Confidential Information as it uses for its own confidential or like information, but in no event, less than
a reasonable degree of care; (2) shall use such Confidential Information only for the purposes contemplated by the parties upon entering
into this Agreement; (3) may not reverse engineer, disassemble, decompile, unencrypt, extract or copy the Confidential Information; (4)
may not, directly or indirectly (including in the conduct of its business), use, or permit to be used, the Confidential Information to
the Company’s detriment.
12.1.3
Limited Use; Destruction. All Confidential Information contained in files, letters, memoranda, reports, records, data, sketches,
drawings, laboratory notebooks, program listings, or other written, photographic, or other tangible material that the Consultant creates
or that comes into its custody or possession, may be used by the Consultant only for the purposes contemplated by the parties upon entering
into this Agreement. Within thirty (30) days of any written request of the Company, the Consultant shall destroy all of its copies of
such Confidential Information or return the same to the Company and, in either case, certify to the Company its compliance with the terms
of this provision. After such destruction or return thereof, the Consultant shall not retain any copies thereof or any such tangible
property.
12.1.4
Limited Release. The Consultant may release Confidential Information to its attorneys or the courts in prosecuting or defending
any claim under this Agreement or pursuant to an order of a court or government agency, provided, however, that in the case of release
pursuant to this section, the Consultant shall limit the release to the greatest extent reasonably possible under the circumstances and
shall have provided to the Company sufficient advance notice to permit the Company to seek a protective order or other order protecting
its Confidential Information from being so disclosed.
12.2
Company’s Property. The Consultant acknowledges that any discovery, concept, or idea, whether patentable or not, including,
but not limited to, any apparatus, process, method, technique, or formula, as well as improvements thereof or know-how related thereto,
relating to any present or prospective activities of the Company and its affiliates (each, an “Invention”) made or
conceived of by the Consultant, either solely or jointly with others, for so long as this Agreement is in effect and for a period of
one (1) year thereafter if such Inventions were conceived of for the Company’s purposes, or have the effect of competing with the
Company’s business, shall be the sole and exclusive property of the Company.
12.3
Intellectual Property Assignment. The Consultant hereby, without royalty or any other additional consideration, (1) assigns to
the Company all of the Consultant’s right, title and interest in and to the Inventions, any applications for United States and
foreign letters patent, any continuations, divisions, continuations-in-part, reissues, extensions or additions thereof filed for upon
the Inventions and any United States and foreign letters patent, (2) covenants to assign to the Company all future Inventions, applications,
continuations, divisions, continuations-in-part, reissues, extensions or additions pursuant to this Agreement, (3) covenants to inform
the Company promptly and fully of the Inventions by written reports, setting forth in detail a description, the operation and the results
achieved, (4) covenants to assist the Company or its designees, at the Company’s expense, to obtain, maintain and enforce such
United States and foreign letters patent for the Inventions as the Company may elect in its sole discretion and (5) covenants to execute,
acknowledge, and deliver to the Company, at the Company’s expense, any written documents and instruments, and do any other acts,
as may be necessary in the Company’s reasonable opinion to obtain, maintain or enforce the United States and foreign letters patent
upon the Inventions and to vest in the Company the entire right and title in, and to confirm the Company’s complete ownership of,
the Inventions.
12.4
Work for Hire. Any material and information created by the Consultant in the course of, or as a result of, the Consultant’s
engagement by the Company that is fixed in a tangible medium of expression, including, but not limited to, notes, drawings, memoranda,
correspondence, documents, work papers, photographs, prototypes, records, notebooks, flow charts, computer programs and source and object
codes, regardless of the medium in which it is fixed (each, a “Work”) will be and remain exclusively the property of the
Company. Each such Work is a “work for hire” within the meaning and purview of the Copyright Act of 1976, 17 USC § 101,
and the Company may file applications to register copyright as the author thereof. The Consultant shall take whatever steps and do whatever
acts the Company requests, including, but not limited to, placement of the Company’s copyright notice on such Works to secure or
aid in securing copyright protection and shall assist the Company or its designees in filing applications to register claims of copyright
in such works. The Consultant may not reproduce, distribute, display publicly, or perform publicly, alone or in combination with any
data processing or network system, any Works without written permission from the Company.
12.5
Covenant Not to Compete. During the Term and for a period of two (2) years thereafter, the Consultant agrees that the Consultant
will not participate in or finance, directly or indirectly, for the Consultant or on behalf of any third party, anywhere in the world,
as principal, agent, employee, employer, consultant, investor or partner, or assist in the management of, or own any stock or any other
ownership interest in, any business that is materially competitive with the business of the Company and/or any of its subsidiaries, as
conducted at any time during the twelve-month period prior to the time in question. Notwithstanding the foregoing, the ownership of not
more than five percent (5%) of the outstanding securities of any company listed on any public exchange or regularly traded in the over-the-counter
market, provided that the Consultant’s involvement with any such company is solely that of a passive security holder and
the Consultant discloses such ownership in advance to the Company’s Board of Directors, shall not constitute a violation of this
paragraph.
12.6
Covenant Not to Solicit. The Consultant agrees to no, during the Term and for a period of two (2) years thereafter: (a)
directly or indirectly, request or advise any of the customers, distributors, or dealers of the Company or any of its subsidiaries to
terminate or curtail their business with the Company or any of its subsidiaries, or to patronize another business which is materially
competitive with the Company or any of its subsidiaries; or (b) directly or indirectly, on behalf of himself or any other person or entity,
request, advise or solicit any employee, consultant or independent contractor of the Company or any of its subsidiaries to leave such
employment or position for any reason.
12.7
Judicial Modification. In the event that any court of law or equity shall consider or hold any aspect of this Section 12 to be
unreasonable or otherwise unenforceable, the parties hereto agree that the aspect of this Section so found may be reduced or modified
by an appropriate order of the court and shall thereafter continue, as so modified, in full force and effect.
12.8
Injunctive Relief. The parties hereto acknowledge that the remedies at law for breach of this Section 12 will be inadequate and
that the Company shall be entitled to injunctive relief for violation thereof; provided, however, that nothing herein contained shall
be construed as prohibiting the Company from pursuing any other remedies available for such breach or threatened breach, including the
recovery of damages from the Consultant.
[Signatures
on Following Page]
IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the date set forth above.
COMPANY |
|
|
|
Intelligent
Bio Solutions Inc. |
|
|
|
|
By:
|
/s/Spiro
Sakiris |
|
Name: |
Spiro
Sakiris |
|
Title: |
CFO |
|
|
|
|
Date: |
February
29th 2024 |
|
CONSULTANT |
|
|
|
C2C
Advisors Inc. |
|
|
|
|
By:
|
/s/
Anthony DaCosta |
|
Name:
|
Anthony
DaCosta |
|
Title:
|
Partner |
|
|
|
|
Date:
|
2/1/24 |
|
Exhibit
A
[***]
v3.24.0.1
Cover
|
Feb. 29, 2024 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Feb. 29, 2024
|
Entity File Number |
001-39825
|
Entity Registrant Name |
INTELLIGENT
BIO SOLUTIONS INC.
|
Entity Central Index Key |
0001725430
|
Entity Tax Identification Number |
82-1512711
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
142
West, 57th Street
|
Entity Address, Address Line Two |
11th
Floor
|
Entity Address, City or Town |
New
York
|
Entity Address, State or Province |
NY
|
Entity Address, Postal Zip Code |
10019
|
City Area Code |
(646)
|
Local Phone Number |
828-8258
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common
Stock, $0.01 par value
|
Trading Symbol |
INBS
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Intelligent Bio Solutions (NASDAQ:INBS)
Historical Stock Chart
From May 2024 to Jun 2024
Intelligent Bio Solutions (NASDAQ:INBS)
Historical Stock Chart
From Jun 2023 to Jun 2024